J&J buys cancer drugmaker Halda for $3bn in latest biotech deal
Pharma group hopes acquisition will help to offset losses from expiring patents on blockbuster drugs
Related reading
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Abbott strikes $23bn deal for Cologuard cancer test maker Exact Sciences
Transaction continues a frenzy of M&A activity this year in the healthcare sector
Hims shares shoot up after weight-loss drug deal with Novo Nordisk
US telehealth group and Danish drugmaker have been in dispute over copycat medicines
Biotech rally mints huge profits for hedge funds
Wave of M&A fuels rally as big pharma groups hunt for blockbusters ahead of patent cliff